| Title |
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
|
|---|---|
| Published in |
Investigational New Drugs, August 2012
|
| DOI | 10.1007/s10637-012-9869-8 |
| Pubmed ID | |
| Authors |
Kenneth J. Pienta, Jean-Pascal Machiels, Dirk Schrijvers, Boris Alekseev, Mikhail Shkolnik, Simon J. Crabb, Susan Li, Shobha Seetharam, Thomas A. Puchalski, Chris Takimoto, Yusri Elsayed, Fitzroy Dawkins, Johann S. de Bono |
Mendeley readers
The data shown below were compiled from readership statistics for 194 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 2 | 1% |
| China | 1 | <1% |
| France | 1 | <1% |
| Unknown | 190 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 37 | 19% |
| Researcher | 24 | 12% |
| Student > Bachelor | 22 | 11% |
| Student > Master | 21 | 11% |
| Other | 14 | 7% |
| Other | 32 | 16% |
| Unknown | 44 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 18% |
| Agricultural and Biological Sciences | 33 | 17% |
| Biochemistry, Genetics and Molecular Biology | 28 | 14% |
| Immunology and Microbiology | 12 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 6% |
| Other | 24 | 12% |
| Unknown | 52 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 April 2022.
All research outputs
#2,572,767
of 23,563,389 outputs
Outputs from Investigational New Drugs
#58
of 1,197 outputs
Outputs of similar age
#17,235
of 170,434 outputs
Outputs of similar age from Investigational New Drugs
#1
of 14 outputs
Altmetric has tracked 23,563,389 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,197 research outputs from this source. They receive a mean Attention Score of 4.8. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 170,434 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.